Anti‐interleukin‐6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus
Open Access
- 3 August 2006
- journal article
- Published by Wiley in Immunology
- Vol. 119 (3), 296-305
- https://doi.org/10.1111/j.1365-2567.2006.02433.x
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease resulting from dysregulation of the immune system. Interleukin-6 (IL-6) is a multifunctional cytokine produced by macrophages, monocytes and T and B cells. It stimulates B-cell differentiation/maturation, immunoglobulin secretion, and T-cell functions. Elevated levels of IL-6 in serum, urine and renal glomeruli were detected in patients with active SLE and in murine models of SLE. Our study investigated the role of IL-6 in an SLE-like disease in New Zealand Black/White (NZB/W) F1 mice by administration of an anti-murine IL-6 monoclonal antibody (mAb). Intraperitoneal administration of the anti-IL-6 mAb suppressed the production of anti-dsDNA autoantibody. B-cell proliferation induced by anti-IgM and anti-CD40 was lower in the anti-IL-6 mAb-treated mice, ex vivo studies demonstrated that anti-IL-6 mAb treatment inhibited anti-dsDNA production. Anti-CD3-induced T-cell proliferation and mixed lymphocyte reactions were inhibited by anti-IL-6 mAb treatment, indicating a partial down-regulation of T cells. Histological analysis showed that treatment with anti-IL-6 mAb prevented the development of severe kidney disease. These results suggest that treatment with anti-IL-6 mAb has a beneficial effect on autoimmunity in murine SLE and that autoreactive B cells may be the primary target for anti-IL-6 mAb treatment; its effect on autoreactive T cells is also indicated.Keywords
This publication has 26 references indexed in Scilit:
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006
- New treatments for SLE: cell-depleting and anti-cytokine therapiesBest Practice & Research Clinical Rheumatology, 2005
- The therapy of autoimmune diseases by anti-interleukin-6 receptor antibodyExpert Opinion on Biological Therapy, 2005
- INTERLEUKIN-6: From Basic Science to Medicine—40 Years in ImmunologyAnnual Review of Immunology, 2005
- Rationale for interleukin-6 blockade in systemic lupus erythematosusLupus, 2004
- The classification of glomerulonephritis in systemic lupus erythematosus revisitedKidney International, 2004
- A Critical Role for Stat3 Signaling in Immune ToleranceImmunity, 2003
- From T to B and back again: positive feedback in systemic autoimmune diseaseNature Reviews Immunology, 2001
- Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptorsOncogene, 2000
- Interleukin 6 promotes murine lupus in NZB/NZW F1 mice.JCI Insight, 1994